The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors.
Monica Arnedos
Consultant or Advisory Role - Merrimack
Research Funding - Merrimack
Crystal Shereen Denlinger
Research Funding - ImClone Systems; Merrimack
Wael A. Harb
Research Funding - Horizon Oncology Research; Merrimack
Olivier Rixe
Research Funding - Merrimack; Sanofi
John Charles Morris
Research Funding - Merrimack
Grace K. Dy
Research Funding - Merrimack
Alex A. Adjei
Research Funding - Merrimack
Joseph Pearlberg
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Sarah Follows
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
Akos Gabor Czibere
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
Jean-Charles Soria
Research Funding - Merrimack; Sanofi